Experts in Injectable Drug Delivery
Owen Mumford Pharmaceutical Services creates award-winning, patient-centric devices and its auto-injectors and pens are distributed around the world.
With more than 70 years’ experience in medical devices, Owen Mumford has a global presence extending from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany, and France.
The Pharmaceutical Services division specialises in the design and manufacture of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries. This includes auto-injectors and pens for subcutaneous and intramuscular administration. Pharmaceutical partners can choose between single and multi-dose, and reusable and disposable devices.
The UniSafe® Platform
Flagship products include the UniSafe® platform, a spring-free, passive safety device for 1ml and 2.25ml pre-filled syringes. UniSafe 1ml has regulatory approval as a combination product in Asia and Europe, where it is also in patient use.
An upcoming addition to this platform is the UniSafe® 1ml auto-injector, a reusable device for use with a 1mL UniSafe safety syringe. This is the only part which is disposed of following use, helping to reduce waste. The auto-injector will be available with optional inbuilt connectivity via automatic Bluetooth® connection, enabling data transfer of key medication parameters between patients and their healthcare providers.
To accommodate a range of different drug fill volumes, our two-step disposable auto-injector, Aidaptus®, can be used with both 1mL and 2.25mL syringes in the same base device. It can also readily adapt to different fill volumes using auto-adjust plunger technology, providing a solution for formulation changes during development and life cycle management. In sum, if the drug formulation has to change, this device does not.
Aidaptus has a unique, patient-centric design with automatic needle insertion for a simple and consistent user experience. The stopper sensing technology, coupled with independent, two-phase needle insertion and drug delivery, significantly reduces any impact forces on the syringe, mitigating the risk of syringe breakages during use.
With a needle that is shielded before, during, and after use, Aidaptus reassures users who are new to auto-injectors, as well as those who are needle-phobic. The device also gives users confidence that the injection has been successfully completed, with an audible notification at the start and end of the procedure.
Owen Mumford Pharmaceutical Services has an exclusive agreement with Stevanato Group for the manufacture of Aidaptus, which was awarded a distinction in the prestigious Red Dot awards for innovative product design. Stevanato Group is a global provider of drug containment, drug delivery, and diagnostic solutions. This collaboration aims to reduce supply chain risk in combination product development for our pharmaceutical partners.
Posted Date: 12/1/2023
This record has been viewed 1636 times.